-
Clinical Trial
Weekly docetaxel as II line therapy in non-small cell lung cancer: an interim analysis of a phase II study.
- M R Valerio, A Russo, M A Latteri, G Modica, G Gulotta, M G Armata, E Bajardi, G Cicero, G Pantuso, N Grassi, G Agosta, and N Gebbia.
- Servizio di Chemioterapia, Policlinico Universitario P.Giaccone, Via del Vespro, 127-90127, Palermo, Italy.
- Lung Cancer. 2001 Dec 1; 34 Suppl 4: S31-5.
AbstractTo evaluate the efficacy and toxicity of weekly docetaxel (D) as II line treatment in non-small cell lung cancer (NSCLC), in November 1999, we started a phase II study on advanced (stages IIIB-IV) NSCLC patients pre-treated with at least one platinum-based chemotherapy regimen with or without radiotherapy. The schedule consisted of D 40 mg/m(2), weekly for 6 weeks, followed by a rest period of 2 weeks, for three cycles or until progression. Eligibility criteria were: histopathologic diagnosis of NSCLC; age
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*,_underline_or**bold**. - Superscript can be denoted by
<sup>text</sup>and subscript<sub>text</sub>. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3., hyphens-or asterisks*. - Links can be included with:
[my link to pubmed](http://pubmed.com) - Images can be included with:
 - For footnotes use
[^1](This is a footnote.)inline. - Or use an inline reference
[^1]to refer to a longer footnote elseweher in the document[^1]: This is a long footnote..